Investors & strategic partners
Galibra Neuroscience is pursuing gene-based therapies for GABA disorders, connecting clinical insight with translational research.
COMPANY OVERVIEW
Research focused on genetic disorders affecting GABA biology, with additional programs in broader neurological conditions.
Founded in 2023 by a clinician and a scientist from Boston Children’s Hospital, affiliated with Harvard Medical School.
Connecting clinical care, scientific research, and patient perspectives to pursue disease-modifying therapies.
RESEARCH & DEVELOPMENT
Program activities are shown as reported in Galibra’s published pipeline. Contact our team for the latest development status and supporting data.
On smaller screens, scroll the tables horizontally to see all program details.
| Program | Indication | Activity shown in pipeline |
|---|---|---|
| GAL005 | SSADH deficiency (SSADHD) | AAV toxicology studies |
| GAL101 | SLC6A1 | AAV efficacy testing in vivo |
| GAL201 | GABA-A variants | Construct validation |
| GAL301 | GABA-T deficiency | Mouse model validation |
| Program | Indication | Activity shown in pipeline |
|---|---|---|
| GAL401 | Drug-resistant epilepsy | Proof of concept in vivo |
| GAL501 | Undisclosed neurological condition | Concept validation |
Source: Galibra’s published pipeline graphic. AAV = adeno-associated virus. Research activities do not establish clinical safety or efficacy.
LEADERSHIP & ADVISORS
Co-Founder
Joseph J. Volpe Chair and Professor of Neurology at Harvard Medical School and Boston Children’s Hospital where he directs the Epilepsy Monitoring Unit and the Neuromodulation Program. Physician-scientist specializing in epilepsy and neural circuit dysfunction. He provides scientific leadership for Galibra’s therapeutic strategy targeting GABA-related neurological disorders.
Co-Founder
Neuroscientist at Harvard Medical School and Boston Children’s Hospital specializing in inhibitory neurotransmission and translational neuroscience. His research focuses on mechanisms regulating GABAergic signaling and neurological disease. Leads preclinical development of Galibra’s gene therapy programs targeting disorders of GABA metabolism.
Chief Development Officer
Rare disease parent, Founder and CEO of SLC6A1 Connect, a global nonprofit advancing research for SLC6A1-related disorders. Former equity research analyst at Janus Henderson Investors and RK Capital Management. Parent of a child with SLC6A1 deficiency. Leads development strategy and patient engagement for Galibra.
Chief Financial Officer
Rare disease parent, Founder and President of the SSADH Association and former President and CEO of Arandell Corporation. Parent of a child with SSADH deficiency. Brings more than 30 years of executive leadership experience and leads business development and strategic partnerships for Galibra.
Clinical Study Advisor
William G. Lennox Chair and Professor of Neurology at Harvard Medical School and Boston Children’s Hospital and Director of Epilepsy and Clinical Neurophysiology. International expert in pediatric epilepsy and metabolic neurological disorders, including SSADH deficiency.
AAV Manufacturing Advisor
Penelope Booth Rockwell Professor at UMass Chan Medical School and Director of the Horae Gene Therapy Center. Pioneer in AAV gene therapy and discovery of multiple viral vector serotypes widely used in gene therapy research and clinical development.
For investment, scientific collaboration, and strategic partnership enquiries, contact our co-founders. Ask about current program status, supporting research, and opportunities to work together.
Henry.Lee@galibraneuroscience.com
Alexander.Rotenberg@galibraneuroscience.com
Copyright © 2026 – GALIBRA NEUROSCIENCE • All Rights Reserved
